Celldex Therapeutics CLDX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$258.76M-63.9% | -$157.86M-11.6% | -$141.43M-25.9% | -$112.33M-59.3% | ||
| $3.38M+6.4% | $3.18M+5.6% | $3.01M+3.9% | $2.9M-5.6% | ||
| $36.22M+5.8% | $34.24M+43.3% | $23.89M+53.0% | $15.61M+74.4% | ||
| -$12K+25.0% | -$16K— | —— | —— | ||
| $11.03M-5.2% | $11.63M+24.0% | $9.38M+200% | $3.12M-14.5% | ||
| —— | —— | -$5.9M-158% | $10.13M— | ||
| —— | -$5.64M— | —— | —— | ||
| $1.32M+168% | -$1.93M-185% | $2.28M+1,203% | $175K+111% | ||
| -$210.95M-33.7% | -$157.78M-47.1% | -$107.29M-3.4% | -$103.73M-70.3% | ||
| $2.71M+41.4% | $1.92M+5.6% | $1.82M-0.5% | $1.83M+46.4% | ||
| $209.07M— | —— | -$105.78M-218% | $89.94M+142% | ||
| —— | —— | $216.22M— | —— | ||
| $2.39M-99.5% | $441.45M+102% | $218.46M+5,260% | $4.08M-98.5% | ||
| —— | —— | $5.39M— | —— | ||
| $5.86M-62.8% | $15.75M+153% | $6.22M— | —— | ||
| $1.32M+168% | -$1.93M-185% | $2.28M+1,203% | $175K+111% | ||
| $3.61M-62.5% | $9.64M+321,233% | $3K— | —— | ||
| —— | —— | -$5.9M-158% | $10.13M— | ||
| -$258.76M-63.9% | -$157.86M-11.6% | -$141.43M-25.9% | -$112.33M-59.3% | ||
| $2.39M-73.9% | $9.15M+309% | $2.24M-45.1% | $4.08M+62.8% | ||
| —— | —— | —— | —— | ||
| -$213.66M-33.8% | -$159.7M-46.4% | -$109.11M-3.4% | -$105.56M-69.8% | ||
| -$213.66M-33.8% | -$159.7M-46.4% | -$109.11M-3.4% | -$105.56M-69.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Celldex Therapeutics's cash flow data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.